000 05950cam a2200649Ia 4500
001 sulb-eb0031647
003 BD-SySUS
005 20170713221306.0
006 m o d
007 cr |n|---|||||
008 120409s2012 njua ob 001 0 eng d
040 _aEBLCP
_beng
_epn
_cEBLCP
_dOCLCQ
_dMHW
_dDG1
_dYDXCP
_dMYG
_dOCLCQ
_dHEBIS
_dOCLCF
_dOCLCA
_dOCLCQ
_dS3O
_dOCLCQ
_dDEBBG
_dBD-SySUS
020 _a9783527632909
_q(electronic bk.)
020 _a3527632905
_q(electronic bk.)
020 _z9783527651252
020 _z352765125X
029 1 _aAU@
_b000049569125
029 1 _aNZ1
_b15900693
029 1 _aDEBBG
_bBV043394438
035 _a(OCoLC)784885298
050 4 _aRS380
_b.P488 2012eb
082 0 4 _a615.1
_223
049 _aMAIN
245 0 0 _aPharmaceutical biotechnology :
_bdrug discovery and clinical applications.
250 _a2nd rev. ed. /
_bedited by Oliver Kayser, Heribert Warzecha.
260 _aHoboken :
_bJohn Wiley & Sons,
_c2012.
300 _a1 online resource (xxvii, 647 pages) :
_billustrations
336 _atext
_btxt
_2rdacontent
337 _acomputer
_bc
_2rdamedia
338 _aonline resource
_bcr
_2rdacarrier
500 _aPrevious edition: 2004.
504 _aIncludes bibliographical references and index.
505 0 _aCover; Related Titles; Title page; Copyright page; Preface to the 2nd Edition; List of Contributors; Part One: Concepts and Methods for Recombinant Drug Production; 1 Pharmaceutical Biotechnology and Industrial Applications -- Learning Lessons from Molecular Biology; 1.1 Introduction; 1.2 Research Developments; 1.3 Production Hosts and Upstream/Downstream Processing; 1.4 Future Outlook; 2 Prokaryotic Cells in Biotech Production; 2.1 Introduction; 2.2 Production of Natural Products by Microorganisms; 2.3 Prokaryotes as Producers of Recombinant Therapeutic Proteins.
505 8 _a3 Mammalian Cells in Biotech Production3.1 Introduction; 3.2 Process Concepts and Cells; 3.3 CHO-Derived Production Cell Lines; 3.4 Rapid Generation of High-Producing Cell Lines; 3.5 Silencing -- Stability of Expression; 3.6 High-Throughput Bioprocess Development; 3.7 Disposable Bioreactors; 3.8 Transient Gene Expression (TGE); 3.9 Conclusions; 4 Biopharmaceuticals from Plants; 4.1 Introduction; 4.2 Basics in Plant Biotechnology; 4.3 Plant Cell Cultures as Production System for Human Glucocerebrosidase; 4.4 Insulin from Safflower -- A Unique Purification Scheme.
505 8 _a4.5 Fast and Scalable Transient Tobacco-Based Expression Systems4.6 Conclusion; 5 Production of Biopharmaceuticals in Transgenic Animals; 5.1 Introduction; 5.2 Sites of Production; 5.3 Transgenic Constructs; 5.4 Methods for the Production of Transgenic Animals; 5.5 Analysis of Transgenic Animals; 5.6 Quality and Safety of the Product; 5.7 Conclusions and Outlook; 6 Translation of New Technologies in Biomedicines: Shaping the Road from Basic Research to Drug Development and Clinical Application -- and Back Again; 6.1 Drug Discovery and Development; 6.2 The Nature of Models and the Need for Them.
505 8 _a6.3 New Technologies Toolbox6.4 Strategic Use of the New Technology Tools; 6.5 Translation as a Two-Way Process; 6.6 Concluding Comment; Part Two: Bringing the Drug into Action -- From Downstreaming to Approval; 7 Overview and Classification of Approved Recombinant Drugs; 7.1 Introduction; 7.2 Classification of Recombinant Drugs from a Technical Point of View; 7.3 Expression Systems; 7.4 Proteins Derived from Modified Genes; 7.5 Artificial Proteins; 7.6 Post-expression Modifications of Recombinant Proteins; 7.7 Biosimilars; 8 Downstream Processing; 8.1 Introduction.
505 8 _a8.2 General Principles of DSP8.3 Clarification; 8.4 Chromatography; 8.5 Ultrafiltration/Diafiltration, and Virus Filtration; 8.6 Crystallization; 8.7 Recent Developments in Downstream Processing; 9 Characterization of Recombinant Proteins; 9.1 Introduction; 9.2 Physical Chemical Characterization; 9.3 Biological Characterization of Biopharmaceuticals In Vitro; Acknowledgments; Legals; 10 Formulation Strategies for Recombinant Protein and Related Biotech Drugs; 10.1 Introduction; 10.2 Formulation and Stability of Protein Solutions; 10.3 Formulation of Vaccines.
505 8 _a11 Drug Approval in the European Union and United States.
520 _a"This second edition of a very successful book is thoroughly updated with existing chapters completely rewritten while the content has more than doubled from 16 to 36 chapters. As with the first edition, the focus is on industrial pharmaceutical research, written by a team of industry experts from around the world, while quality and safety management, drug approval and regulation, patenting issues, and biotechnology fundamentals are also covered. In addition, this new edition now not only includes biotech drug development but also the use of biopharmaceuticals in diagnostics and vaccinations."--Provided by publisher.
588 0 _aPrint version record.
650 0 _aPharmaceutical biotechnology.
650 7 _aPharmaceutical biotechnology.
_2fast
_0(OCoLC)fst01060106
650 7 _aPharmazeutische Technologie
_2gnd
_0(DE-588)4045699-7
650 7 _aBiotechnologie
_2gnd
_0(DE-588)4069491-4
650 7 _aBioteknik.
_2sao
655 4 _aElectronic books.
700 1 _aKayser, Oliver.
700 1 _aWarzecha, Heribert.
710 2 _aWiley InterScience (Online service)
776 0 8 _iPrint version:
_aKayser, Oliver.
_tPharmaceutical Biotechnology : Drug Discovery and Clinical Applications.
_dHoboken : John Wiley & Sons, ©2012
_z9783527329946
_w(OCoLC)794134901
856 4 0 _uhttp://onlinelibrary.wiley.com/book/10.1002/9783527632909
_zWiley Online Library [Free Download only for SUST IP]
938 _aEBL - Ebook Library
_bEBLB
_nEBL875950
938 _aYBP Library Services
_bYANK
_n7607353
938 _aYBP Library Services
_bYANK
_n7644123
938 _aYBP Library Services
_bYANK
_n7585093
994 _a92
_bDG1
999 _c63299
_d63299